INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against InVivo Therapeutics Holdings Corp.

Glancy Binkow & Goldberg LLP reminds investors of InVivo Therapeutics Holdings Corp. (“InVivo” or the “Company”) (OTC:NVIV)that all purchasers of InVivo securities between April 5, 2013 and August 26, 2013, inclusive (the “Class Period”), have until October 6, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

InVivo develops biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. The Complaint alleges that defendants made false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, defendants misrepresented and/or failed to disclose that the Company’s clinical study for its biopolymer scaffolding to treat acute spinal cord injuries would not be completed with all data submitted to the FDA by the end of 2014, and the Company did not anticipate completing this clinical study until late 2015. As a result, the Company’s statements about its clinical study timeline for biopolymer scaffolding to treat acute spinal cord injuries were materially false and misleading and/or lacked a reasonable basis.

If you are a member of the Class described above, you may move the Court no later than October 6, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at 888-773-9224, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts:

Glancy Binkow & Goldberg LLP, Los Angeles
Lesley Portnoy
888-773-9224
310-201-9150
shareholders@glancylaw.com
www.glancylaw.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.